Abstract
This review article highlights some important points in the evolving area of predictive biomarkers determination in non-small-cell lung cancer toward standardization of testing practices, including EGFR mutations, ALK and ROS1 rearrangements and immunohistochemical expression of PD-L1. Considerations for selecting appropriate populations for molecular testing, and emergence of other targetable molecular alterations are also discussed.
Keywords:
ALK; Carcinoma; EGFR; FISH; Immunoistochemistry; Lung; PCR; PDL1; ROS1.
Copyright © 2018 Società Italiana di Anatomia Patologica e Citopatologia Diagnostica, Divisione Italiana della International Academy of Pathology.
MeSH terms
-
Anaplastic Lymphoma Kinase / genetics*
-
B7-H1 Antigen / metabolism
-
Biomarkers, Tumor / genetics*
-
Biomarkers, Tumor / metabolism
-
Biopsy
-
Carcinoma, Non-Small-Cell Lung / diagnosis
-
Carcinoma, Non-Small-Cell Lung / genetics*
-
Carcinoma, Non-Small-Cell Lung / metabolism
-
Carcinoma, Non-Small-Cell Lung / pathology
-
ErbB Receptors / genetics
-
Gene Rearrangement
-
Humans
-
Immunohistochemistry
-
In Situ Hybridization, Fluorescence
-
Lung Neoplasms / diagnosis
-
Lung Neoplasms / genetics*
-
Lung Neoplasms / metabolism
-
Lung Neoplasms / pathology
-
Mutation
-
Pathologists
-
Pathology, Molecular
-
Protein-Tyrosine Kinases / genetics*
-
Proto-Oncogene Proteins / genetics*
Substances
-
B7-H1 Antigen
-
Biomarkers, Tumor
-
CD274 protein, human
-
Proto-Oncogene Proteins
-
ALK protein, human
-
Anaplastic Lymphoma Kinase
-
EGFR protein, human
-
ErbB Receptors
-
Protein-Tyrosine Kinases
-
ROS1 protein, human